» Articles » PMID: 33072859

Maltotriose Conjugated Metal-Organic Frameworks for Selective Targeting and Photodynamic Therapy of Triple Negative Breast Cancer Cells and Tumor Associated Macrophages

Abstract

Herein, we report a nano-MOF conjugated to maltotriose as a new DDS. MA-PCN-224-0.1Mn/0.9Zn showed its ability to target cancer and TAM. This novel MOF is an effective PDT agent and shows little dark toxicity, MA-PCN-224-0.1Mn/0.9Zn uptakes selectively into cancer cells. A well-suited size control methodology was used so that the nano-scaled MOFs may take advantage of the EPR effect. This development of a nano-scale MOF for PDT that is conjugated to a cancer targeting ligand represents a meaningful development for the use of MOFs as drug delivery systems.

Citing Articles

Multifunctional nanostructures: Intelligent design to overcome biological barriers.

Azizi M, Jahanban-Esfahlan R, Samadian H, Hamidi M, Seidi K, Dolatshahi-Pirouz A Mater Today Bio. 2023; 20:100672.

PMID: 37273793 PMC: 10232915. DOI: 10.1016/j.mtbio.2023.100672.


Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.

Zhan C, Jin Y, Xu X, Shao J, Jin C Cancer Med. 2023; 12(10):11049-11072.

PMID: 36794651 PMC: 10242868. DOI: 10.1002/cam4.5489.


Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer.

Dias C, Helguero L, Faustino M Molecules. 2021; 26(24).

PMID: 34946732 PMC: 8709347. DOI: 10.3390/molecules26247654.


A Bio-Conjugated Chlorin-Based Metal-Organic Framework for Targeted Photodynamic Therapy of Triple Negative Breast and Pancreatic Cancers.

Sakamaki Y, Ozdemir J, Heidrick Z, Azzun A, Watson O, Tsuji M ACS Appl Bio Mater. 2021; 4(2):1432-1440.

PMID: 34337346 PMC: 8320713. DOI: 10.1021/acsabm.0c01324.

References
1.
Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

2.
Liberti M, Locasale J . The Warburg Effect: How Does it Benefit Cancer Cells?. Trends Biochem Sci. 2016; 41(3):211-218. PMC: 4783224. DOI: 10.1016/j.tibs.2015.12.001. View

3.
Hayashi N, Kataoka H, Yano S, Tanaka M, Moriwaki K, Akashi H . A novel photodynamic therapy targeting cancer cells and tumor-associated macrophages. Mol Cancer Ther. 2014; 14(2):452-60. DOI: 10.1158/1535-7163.MCT-14-0348. View

4.
Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z . M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo). 2011; 66(11):1879-86. PMC: 3203959. DOI: 10.1590/s1807-59322011001100006. View

5.
Roca H, Varsos Z, Sud S, Craig M, Ying C, Pienta K . CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009; 284(49):34342-54. PMC: 2797202. DOI: 10.1074/jbc.M109.042671. View